Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Income from Continuing Operations (2021 - 2025)

Prime Medicine's Income from Continuing Operations history spans 5 years, with the latest figure at 47525000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 12.42% year-over-year to 47525000.0; the TTM value through Dec 2025 reached 204838000.0, down 4.57%, while the annual FY2025 figure was 204201000.0, 4.25% down from the prior year.
  • Income from Continuing Operations reached 47525000.0 in Q4 2025 per PRME's latest filing, up from 52832000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 16412000.0 in Q3 2021 to a low of 65643000.0 in Q4 2023.
  • Average Income from Continuing Operations over 5 years is 44444277.78, with a median of 46643000.0 recorded in 2024.
  • The largest YoY upside for Income from Continuing Operations was 37.56% in 2022 against a maximum downside of 78.83% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 62911000.0 in 2021, then surged by 37.56% to 39283000.0 in 2022, then tumbled by 67.1% to 65643000.0 in 2023, then surged by 35.6% to 42276000.0 in 2024, then decreased by 12.42% to 47525000.0 in 2025.
  • Per Business Quant, the three most recent readings for PRME's Income from Continuing Operations are 47525000.0 (Q4 2025), 52832000.0 (Q3 2025), and 52591000.0 (Q2 2025).